Doug Ingram is the President and CEO of Sarepta Therapeutics, Inc., a company at the forefront of developing transformative therapies for rare diseases. He earned his MBA from the Wharton School at the University of Pennsylvania, which provides him with...

Doug Ingram is the President and CEO of Sarepta Therapeutics, Inc., a company at the forefront of developing transformative therapies for rare diseases. He earned his MBA from the Wharton School at the University of Pennsylvania, which provides him with a strong background in both business and finance. Under his leadership since 2016, the company has focused heavily on innovative treatments in the pharmaceutical industry, particularly in gene therapy and neuromuscular diseases. Doug’s leadership style is driven by performance metrics that include achieving corporate goals related to product revenue and regulatory advancements. His compensation reflects this, with a significant part based on bonuses tied to these achievements. Notably, Doug has successfully navigated Sarepta through challenging times, maintaining growth and stakeholder confidence. His track record includes substantial insider trading activity, suggesting a strong belief in the company’s future, with high stock value fluctuations indicating both risk and opportunity ahead. He’s been instrumental in driving Sarepta's vision to become a leader in its field.